Navamedic extends product agreement

Navamedic ASA (OSE: NAVA) today announced a three year extension of the Company's distributor agreement for one of its key products.

Navamedic has extended its agreement with Tribute Pharmaceuticals of Canada for Uracyst, a product for the treatment of pain in the urine bladder.

Uracyst is one of the key products in Navamedic's Pharma product portfolio, representing annual sales of more than NOK 5 million. The product has experienced an annual sales growth of more than 20 per cent over the last years, and Navamedic is the Nordic market leader in Uracyst's product area.

For further information, please call Håkan Josephsson, interim CEO, telephone +46 706 742 533 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).